X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6923) 6923
male (4454) 4454
female (4107) 4107
middle aged (3493) 3493
sirolimus (2764) 2764
sirolimus - administration & dosage (2697) 2697
treatment outcome (2672) 2672
aged (2571) 2571
sirolimus - therapeutic use (2264) 2264
cardiac & cardiovascular systems (2087) 2087
sirolimus - analogs & derivatives (2062) 2062
transplantation (1995) 1995
sirolimus - adverse effects (1916) 1916
adult (1821) 1821
everolimus (1717) 1717
rapamycin (1676) 1676
immunosuppressive agents - therapeutic use (1669) 1669
time factors (1567) 1567
surgery (1551) 1551
immunosuppressive agents - adverse effects (1513) 1513
drug-eluting stents (1430) 1430
stents (1280) 1280
animals (1194) 1194
risk factors (1166) 1166
follow-up studies (1045) 1045
stent (1001) 1001
immunosuppressive agents - administration & dosage (991) 991
coronary angiography (978) 978
sirolimus - pharmacology (968) 968
immunology (922) 922
thrombosis (921) 921
implantation (899) 899
retrospective studies (879) 879
prospective studies (859) 859
restenosis (852) 852
prosthesis design (841) 841
oncology (802) 802
coronary artery disease - therapy (752) 752
cyclosporine (751) 751
cardiovascular agents - administration & dosage (734) 734
immunosuppression (733) 733
angioplasty, balloon, coronary - adverse effects (708) 708
kidney transplantation (703) 703
therapy (701) 701
drug-eluting stents - adverse effects (685) 685
care and treatment (680) 680
calcineurin inhibitors (653) 653
tacrolimus (647) 647
analysis (638) 638
tor serine-threonine kinases - antagonists & inhibitors (619) 619
drug therapy, combination (604) 604
efficacy (604) 604
percutaneous coronary intervention (600) 600
cardiovascular (590) 590
recipients (590) 590
mammalian target (579) 579
angioplasty, balloon, coronary - instrumentation (574) 574
graft rejection - prevention & control (568) 568
angioplasty (563) 563
pharmacology & pharmacy (551) 551
paclitaxel - administration & dosage (548) 548
cancer (547) 547
abridged index medicus (541) 541
mycophenolate-mofetil (531) 531
risk assessment (524) 524
coronary restenosis - etiology (512) 512
trial (509) 509
medicine & public health (495) 495
coronary restenosis - prevention & control (488) 488
kidney transplantation - adverse effects (479) 479
research (478) 478
stents - adverse effects (475) 475
kidneys (470) 470
mtor (469) 469
immunosuppressive agents - pharmacology (458) 458
aged, 80 and over (457) 457
kaplan-meier estimate (456) 456
cardiology (452) 452
drug-eluting stent (438) 438
follow-up (438) 438
outcomes (427) 427
health aspects (426) 426
sirolimus-eluting stent (417) 417
percutaneous coronary intervention - adverse effects (416) 416
drug therapy (415) 415
urology & nephrology (415) 415
safety (407) 407
incidence (406) 406
bare-metal stents (404) 404
adolescent (396) 396
disease (387) 387
mycophenolic acid - analogs & derivatives (387) 387
kidney transplantation - immunology (386) 386
mice (385) 385
myocardial infarction - etiology (384) 384
dose-response relationship, drug (378) 378
young adult (377) 377
immunosuppressive agents (376) 376
heart attacks (374) 374
percutaneous coronary intervention - instrumentation (374) 374
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7826) 7826
Japanese (77) 77
French (53) 53
Spanish (43) 43
German (33) 33
Chinese (23) 23
Italian (12) 12
Russian (12) 12
Portuguese (7) 7
Polish (6) 6
Danish (4) 4
Korean (4) 4
Dutch (3) 3
Hungarian (3) 3
Turkish (3) 3
Lithuanian (2) 2
Czech (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Chest, ISSN 0012-3692, 02/2008, Volume 133, Issue 2, pp. 528 - 538
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 06/2016, Volume 27, Issue 5, pp. 383 - 397
.... A systematic review was conducted to assess the clinical efficacy, safety and effect of all first-line treatments evaluated to date on health-related quality of life (HRQoL... 
Metastatic renal cell carcinoma | First-line treatment | Systematic review | Advanced renal cell carcinoma | Treatment-naive patients | TARGETED THERAPY | RESPONSE CRITERIA | PAZOPANIB | PLUS INTERFERON-ALPHA | metastatic renal cell carcinoma | OPEN-LABEL | systematic review | SORAFENIB | advanced renal cell carcinoma | PHASE-III TRIAL | ONCOLOGY | DOUBLE-BLIND | SUNITINIB | PHARMACOLOGY & PHARMACY | first-line treatment | QUALITY-OF-LIFE | treatment-naive patients | Niacinamide - analogs & derivatives | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Carcinoma, Renal Cell - psychology | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Imidazoles - adverse effects | Interferon-alpha - therapeutic use | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Randomized Controlled Trials as Topic | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Quality of Life | Sulfonamides - adverse effects | Indoles - therapeutic use | Kidney Neoplasms - pathology | Interferon-alpha - adverse effects | Quinolines - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Quinolines - adverse effects
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2012, Volume 39, Issue 4, pp. 388 - 401
Abstract Background To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management... 
Hematology, Oncology and Palliative Medicine | Side effects | Adverse events | Targeted therapy | Renal cell carcinoma | MAMMALIAN TARGET | SUNITINIB TREATMENT | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | KINASE INHIBITORS | INTERFERON-ALPHA | ONCOLOGY | RANDOMIZED PHASE-II | NASAL-SEPTUM PERFORATION | QUALITY-OF-LIFE | JAPANESE PATIENTS | FOOT SKIN REACTION | Niacinamide - analogs & derivatives | Humans | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Protein Kinase Inhibitors - adverse effects | Bevacizumab | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Molecular Targeted Therapy - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Imidazoles - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Care and treatment | Metastasis | Carcinoma, Renal cell | Cancer | Index Medicus
Journal Article
European Urology, ISSN 0302-2838, 2007, Volume 53, Issue 5, pp. 917 - 930
Abstract Objective To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of possible preventive or therapeutic measures... 
Urology | Temsirolimus | Side effects | Sunitinib | Sorafenib | sunitinib | MAMMALIAN TARGET | BAY-43-9006 | sorafenib | SAFETY | DAYS ON/7 DAYS | RAF KINASE | TYROSINE KINASE INHIBITORS | FACTOR RECEPTOR INHIBITOR | INTERFERON-ALPHA | temsirolimus | PHARMACOKINETICS | UROLOGY & NEPHROLOGY | side effects | PHASE-I | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor | Drug-Related Side Effects and Adverse Reactions - prevention & control | Prognosis | Humans | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sirolimus - administration & dosage | Indoles - adverse effects | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Metastasis | Life Sciences | Pharmaceutical sciences | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 5, pp. 876 - 884
...). Dose escalation was based on 3+3 design and used the Common Terminology Criteria for Adverse Events Version 4.0... 
Hematology, Oncology and Palliative Medicine | p70 S6 kinase inhibitor | LY2584702 tosylate | Erlotinib | Everolimus | CELL LUNG-CANCER | RAPAMYCIN | PHARMACOKINETICS | ONCOLOGY | PHOSPHORYLATION | GROWTH | TRANSLATION INITIATION | ACTIVE METABOLITE OSI-420 | Erlotinib Hydrochloride | Neoplasms - metabolism | Area Under Curve | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Metabolic Clearance Rate | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Time Factors | Adult | Female | Quinazolines - administration & dosage | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacokinetics | Sirolimus - adverse effects | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Sirolimus - analogs & derivatives | Drug Administration Schedule | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Pyrimidines - administration & dosage | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Vomiting - chemically induced | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Pyrimidines - pharmacokinetics | Anorexia - chemically induced | Aged | Adaptor Proteins, Signal Transducing - metabolism | Neoplasms - pathology | Clinical trials | Care and treatment | Product development | Tumors | Life Sciences | Cancer
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1465-1858, 03/2017, Volume 2017, Issue 10, p. CD011639
Background As part of liver transplantation, immunosuppression (suppressing the host immunity) is given to prevent graft rejections resulting from the immune... 
Liver Transplantation | LIVER TRANSPLANTATION AND RELATED SURGERY (KJJC) (ACCORDING TO NCSP) | Immunosuppressive Agents | Glucocorticoids | Sirolimus | Gastroenterology & hepatology | Liver disorders | Transplantation | Cyclosporine | Mycophenolic Acid | Retreatment | Immunosuppression | Tacrolimus | Maintenance immunosuppression | Bayes Theorem | Transplantation Immunology | Network Meta‐Analysis | Azathioprine | Drug Therapy, Combination | Odds Ratio | Medicine General & Introductory Medical Sciences | Everolimus | TRANSPLANTATION: SOLID ORGAN | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Immunosuppression - methods | Humans | Immunosuppressive Agents - therapeutic use | Immunosuppression - mortality | Immunosuppression - adverse effects | Everolimus - adverse effects | Adult | Everolimus - therapeutic use | Network Meta-Analysis | Glucocorticoids - adverse effects | Sirolimus - adverse effects | Sirolimus - therapeutic use | Liver Transplantation - mortality | Retreatment - statistics & numerical data | Tacrolimus - adverse effects | Cyclosporine - therapeutic use | Mycophenolic Acid - adverse effects | Tacrolimus - therapeutic use | Drug Therapy, Combination - mortality | Mycophenolic Acid - therapeutic use | Cyclosporine - adverse effects | Immunosuppressive Agents - adverse effects | Azathioprine - adverse effects
Journal Article